Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response

PROPOSE: Using Docetaxel chemotherapy or new hormonal agents (NHT) to intensify upfront systemic therapy resulted in improved survival rates compared to androgen deprivation monotherapy (ADT). Hence, combination therapies have become the new standard of care (SOC) in metastatic hormone-sensitive pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kafka, Mona, Burtscher, Thomas, Fritz, Josef, Schmitz, Maximilian, Bektic, Jasmin, Ladurner, Michael, Horninger, Wolfgang, Heidegger, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Topic Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415491/
https://www.ncbi.nlm.nih.gov/pubmed/36287244
http://dx.doi.org/10.1007/s00345-022-04189-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415491/
https://www.ncbi.nlm.nih.gov/pubmed/36287244
http://dx.doi.org/10.1007/s00345-022-04189-8

Ejemplares similares